Business
Vicore Pharma to Present at the 44th Annual J.P. Morgan Healthcare Conference
STOCKHOLM, SE / ACCESS Newswire / January 7, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will ...
About this update from Vicore Pharma Holding Ab
[{"type":"text","content":"STOCKHOLM, SE / ACCESS Newswire / January 7, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will present at the 44th Annual J.P. Morgan Healthcare Conference:","length":312,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Location: Westin St. Francis, San Francisco, USA","length":48,"tagName":"p"}]},{"val":[{"type":"text","content":"Format: Presentation and 1×1 meetings","length":37,"tagName":"p"}]},{"val":[{"type":"text","content":"Presentation Date and Time: Thursday, January 15 at 9:00 AM PST","length":63,"tagName":"p"}]},{"val":[{"type":"text","content":"Webcast: Link","length":13,"tagName":"p"}]},{"val":[{"type":"text","content":"Participants: Ahmed Mousa, CEO, Hans Jeppsson, CFO, Jimmie Hofman, VP of BD, and Megan Richards, VP of IR and Comms","length":115,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":276,"olType":false},{"type":"text","content":"The company's management team will also be available for meetings at the conference.","length":88,"tagName":"p"},{"type":"text","content":"For more information, please contact:Megan Richards, VP of IR and Comms, +1 978 269-4372, [email protected] Jeppsson, CFO, +46 70 553 14 65, [email protected]","length":191,"tagName":"p"},{"type":"text","content":"About Vicore Pharma Vicore Pharma is a clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is a first-in-class oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF.","length":566,"tagName":"p"},{"type":"text","content":"Vicore is publicly listed on the Nasdaq Stockholm exchange with the ticker VICO. www.vicorepharma.com","length":101,"tagName":"p"},{"type":"text","content":"AttachmentsVicore Pharma to present at the 44th Annual J.P. Morgan Healthcare Conference","length":89,"tagName":"p"},{"type":"text","content":"SO...